These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 31762074)

  • 1. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease.
    Palmer M; Regev A; Lindor K; Avigan MI; Dimick-Santos L; Treem W; Marcinak JF; Lewis JH; Anania FA; Seekins D; Shneider BL; Chalasani N
    Aliment Pharmacol Ther; 2020 Jan; 51(1):90-109. PubMed ID: 31762074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis.
    Regev A; Palmer M; Avigan MI; Dimick-Santos L; Treem WR; Marcinak JF; Seekins D; Krishna G; Anania FA; Freston JW; Lewis JH; Sanyal AJ; Chalasani N
    Aliment Pharmacol Ther; 2019 Mar; 49(6):702-713. PubMed ID: 30761572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis.
    Treem WR; Palmer M; Lonjon-Domanec I; Seekins D; Dimick-Santos L; Avigan MI; Marcinak JF; Dash A; Regev A; Maller E; Patwardhan M; Lewis JH; Rockey DC; Di Bisceglie AM; Freston JW; Andrade RJ; Chalasani N
    Drug Saf; 2021 Feb; 44(2):133-165. PubMed ID: 33141341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative histologic features among liver biopsies with biliary-pattern injury and confirmed clinical diagnoses.
    Yu S; Vidal B; Peric M; Rosenbaum MW; Cates JMM; Gonzalez RS
    Hum Pathol; 2024 Apr; 146():8-14. PubMed ID: 38479481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: Recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patients.
    Fettiplace A; Marcinak J; Merz M; Zhang HT; Kikuchi L; Regev A; Palmer M; Rockey D; Fontana R; Hayashi PH; Tillmann HL; Di Bisceglie AM; Lewis JH
    Aliment Pharmacol Ther; 2024 Nov; 60(10):1293-1307. PubMed ID: 39300766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development.
    Regev A; Avigan MI; Kiazand A; Vierling JM; Lewis JH; Omokaro SO; Di Bisceglie AM; Fontana RJ; Bonkovsky HL; Freston JW; Uetrecht JP; Miller ED; Pehlivanov ND; Haque SA; Harrison MJ; Kullak-Ublick GA; Li H; Patel NN; Patwardhan M; Price KD; Watkins PB; Chalasani NP
    J Autoimmun; 2020 Nov; 114():102514. PubMed ID: 32768244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum.
    Palmer M; Kleiner DE; Goodman Z; Brunt E; Avigan MI; Regev A; Hayashi PH; Lewis JH; Mehta R; Harrison SA; Siciliano M; McWherter CA; Vuppalanchi R; Behling C; Miller V; Chalasani N; Sanyal AJ
    Aliment Pharmacol Ther; 2024 Jan; 59(2):201-216. PubMed ID: 37877759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis.
    Yang J; Yu YL; Jin Y; Zhang Y; Zheng CQ
    World J Gastroenterol; 2016 Sep; 22(33):7579-86. PubMed ID: 27672278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed diagnosis of cholestatic drug-induced liver injury treated with corticosteroid for adrenal insufficiency secondary to miliary tuberculosis.
    Lee SY; Schneier A; Schiano T; Liu SJ; Machado ON
    Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3046-9. PubMed ID: 26367727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials.
    Hey-Hadavi J; Seekins D; Palmer M; Coffey D; Caminis J; Abdullaev S; Patwardhan M; Tyler H; Raheja R; Stanley AM; Pineda-Salgado L; Bourdet DL; Andrade RJ; Hayashi PH; Dimick-Santos L; Rockey DC; Estilo A
    Drug Saf; 2021 Jun; 44(6):619-634. PubMed ID: 33725335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations.
    Kleiner DE; Chalasani NP; Lee WM; Fontana RJ; Bonkovsky HL; Watkins PB; Hayashi PH; Davern TJ; Navarro V; Reddy R; Talwalkar JA; Stolz A; Gu J; Barnhart H; Hoofnagle JH;
    Hepatology; 2014 Feb; 59(2):661-70. PubMed ID: 24037963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Aspects in the Management of Cholestatic Liver Diseases.
    Chazouillères O
    Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury.
    Chalasani NP; Maddur H; Russo MW; Wong RJ; Reddy KR;
    Am J Gastroenterol; 2021 May; 116(5):878-898. PubMed ID: 33929376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [An analysis of the serological characteristics of anti-mitochondrial M2 subtype in patients with drug-induced liver injury and primary biliary cholangitis].
    Sun LM; Yan HP; Lou JL; Wang Y; Zhao Y; Yu YH; Zhang HP; Liu YM
    Zhonghua Gan Zang Bing Za Zhi; 2019 Apr; 27(4):298-303. PubMed ID: 31082342
    [No Abstract]   [Full Text] [Related]  

  • 15. Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials.
    Avigan MI; Bjornsson ES; Pasanen M; Cooper C; Andrade RJ; Watkins PB; Lewis JH; Merz M
    Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S19-31. PubMed ID: 25352325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-induced liver injury and drug development: industry perspective.
    Regev A
    Semin Liver Dis; 2014 May; 34(2):227-39. PubMed ID: 24879986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
    Lirussi F; Okolicsanyi L
    Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiology and Diseases of the Proximal Pathways of the Biliary System.
    Nakanishi Y; Saxena R
    Arch Pathol Lab Med; 2015 Jul; 139(7):858-66. PubMed ID: 26125426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cholestatic liver diseases].
    Grimm D; Thimme R
    Ther Umsch; 2011 Apr; 68(4):195-9. PubMed ID: 21452140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative.
    Cohen EB; Patwardhan M; Raheja R; Alpers DH; Andrade RJ; Avigan MI; Lewis JH; Rockey DC; Chui F; Iacob AM; Linardi CC; Regev A; Shick J; Lucena MI
    Drug Saf; 2024 Apr; 47(4):301-319. PubMed ID: 38217833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.